The global lysosomal alpha glucosidase market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of glycogen storage disease and pompe disease, which are the two major diseases that are treated with lysosomal alpha glucosidase enzyme.
The global lysosomal alpha glucosidase market is segmented on the basis of type (A982, AT200, AVRR03, J162, MOSGAA), by application (glycogen storage disease and pompe disease) and by region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa). North America accounted for a share of over 40% in 2018 owing to its high prevalence rates for glycogen storage disease and pompe disease. Europe accounted for a share of over 30% in 2018 owing to its high prevalence rates for glycogen storage disease. Asia Pacific is expected to grow at a CAGR of 6% during the forecast period owing to its low prevalence rates for glycogen storage diseases as compared with other regions such as North America and Europe.
Some Of The Growth Factors Of This Market:
- The global Lysosomal Alpha Glucosidase market is driven by factors such as increasing prevalence of type 2 diabetes and obesity, rising geriatric population, and increasing awareness about the disease among patients and healthcare providers.
- Increasing prevalence of type 2 diabetes and obesity are driving the growth of the global Lysosomal Alpha Glucosidase market due to increased risk for developing complications associated with these diseases such as diabetic retinopathy, nephropathy, neuropathy, cardiovascular disease etc, which in turn increases demand for treatment options like Lysosomal Alpha Glucosidase therapy.
- Rising geriatric population is also driving the growth of this market because people over 65 years old are more prone to develop type 2 diabetes than younger adults.
- Increasing awareness about this disease among patients and healthcare providers is also driving the growth of this market because it helps in early diagnosis which can help in preventing complications associated with this disease.
Industry Growth Insights published a new data on “Lysosomal Alpha Glucosidase Market”. The research report is titled “Lysosomal Alpha Glucosidase Market research by Types (AT-982, ATB-200, AVRRD-03, JR-162, MOSS-GAA, OXY-2810, Others), By Applications (Glycogen Storage Disease, Pompe Disease, Others), By Players/Companies Amicus Therapeutics Inc, Audentes Therapeutics Inc, Etubics Corp, Genzyme Corp, greenovation Biotech GmbH, Huons Co Ltd, JCR Pharmaceuticals Co Ltd, Oxyrane Belgium NV, Pharming Group NV, Sarepta Therapeutics Inc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Lysosomal Alpha Glucosidase Market Research Report
By Type
AT-982, ATB-200, AVRRD-03, JR-162, MOSS-GAA, OXY-2810, Others
By Application
Glycogen Storage Disease, Pompe Disease, Others
By Companies
Amicus Therapeutics Inc, Audentes Therapeutics Inc, Etubics Corp, Genzyme Corp, greenovation Biotech GmbH, Huons Co Ltd, JCR Pharmaceuticals Co Ltd, Oxyrane Belgium NV, Pharming Group NV, Sarepta Therapeutics Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Lysosomal Alpha Glucosidase Market Report Segments:
The global Lysosomal Alpha Glucosidase market is segmented on the basis of:
Types
AT-982, ATB-200, AVRRD-03, JR-162, MOSS-GAA, OXY-2810, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Glycogen Storage Disease, Pompe Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amicus Therapeutics Inc
- Audentes Therapeutics Inc
- Etubics Corp
- Genzyme Corp
- greenovation Biotech GmbH
- Huons Co Ltd
- JCR Pharmaceuticals Co Ltd
- Oxyrane Belgium NV
- Pharming Group NV
- Sarepta Therapeutics Inc
Highlights of The Lysosomal Alpha Glucosidase Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AT-982
- ATB-200
- AVRRD-03
- JR-162
- MOSS-GAA
- OXY-2810
- Others
- By Application:
- Glycogen Storage Disease
- Pompe Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lysosomal Alpha Glucosidase Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lysosomal alpha glucosidase is an enzyme that breaks down glucose into smaller molecules in the body. Glucose is a type of sugar that is used by the body for energy.
Some of the major players in the lysosomal alpha glucosidase market are Amicus Therapeutics Inc, Audentes Therapeutics Inc, Etubics Corp, Genzyme Corp, greenovation Biotech GmbH, Huons Co Ltd, JCR Pharmaceuticals Co Ltd, Oxyrane Belgium NV, Pharming Group NV, Sarepta Therapeutics Inc.
The lysosomal alpha glucosidase market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Lysosomal Alpha Glucosidase Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Lysosomal Alpha Glucosidase Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Lysosomal Alpha Glucosidase Market - Supply Chain
4.5. Global Lysosomal Alpha Glucosidase Market Forecast
4.5.1. Lysosomal Alpha Glucosidase Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Lysosomal Alpha Glucosidase Market Size (000 Units) and Y-o-Y Growth
4.5.3. Lysosomal Alpha Glucosidase Market Absolute $ Opportunity
5. Global Lysosomal Alpha Glucosidase Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Type
5.3.1. AT-982
5.3.2. ATB-200
5.3.3. AVRRD-03
5.3.4. JR-162
5.3.5. MOSS-GAA
5.3.6. OXY-2810
5.3.7. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Lysosomal Alpha Glucosidase Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Application
6.3.1. Glycogen Storage Disease
6.3.2. Pompe Disease
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Lysosomal Alpha Glucosidase Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Lysosomal Alpha Glucosidase Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Lysosomal Alpha Glucosidase Demand Share Forecast, 2019-2026
9. North America Lysosomal Alpha Glucosidase Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Application
9.4.1. Glycogen Storage Disease
9.4.2. Pompe Disease
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Type
9.7.1. AT-982
9.7.2. ATB-200
9.7.3. AVRRD-03
9.7.4. JR-162
9.7.5. MOSS-GAA
9.7.6. OXY-2810
9.7.7. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Lysosomal Alpha Glucosidase Demand Share Forecast, 2019-2026
10. Latin America Lysosomal Alpha Glucosidase Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Application
10.4.1. Glycogen Storage Disease
10.4.2. Pompe Disease
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Type
10.7.1. AT-982
10.7.2. ATB-200
10.7.3. AVRRD-03
10.7.4. JR-162
10.7.5. MOSS-GAA
10.7.6. OXY-2810
10.7.7. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Lysosomal Alpha Glucosidase Demand Share Forecast, 2019-2026
11. Europe Lysosomal Alpha Glucosidase Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Application
11.4.1. Glycogen Storage Disease
11.4.2. Pompe Disease
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Type
11.7.1. AT-982
11.7.2. ATB-200
11.7.3. AVRRD-03
11.7.4. JR-162
11.7.5. MOSS-GAA
11.7.6. OXY-2810
11.7.7. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Lysosomal Alpha Glucosidase Demand Share, 2019-2026
12. Asia Pacific Lysosomal Alpha Glucosidase Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Application
12.4.1. Glycogen Storage Disease
12.4.2. Pompe Disease
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Type
12.7.1. AT-982
12.7.2. ATB-200
12.7.3. AVRRD-03
12.7.4. JR-162
12.7.5. MOSS-GAA
12.7.6. OXY-2810
12.7.7. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Lysosomal Alpha Glucosidase Demand Share, 2019-2026
13. Middle East & Africa Lysosomal Alpha Glucosidase Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Application
13.4.1. Glycogen Storage Disease
13.4.2. Pompe Disease
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Lysosomal Alpha Glucosidase Market Size and Volume Forecast by Type
13.7.1. AT-982
13.7.2. ATB-200
13.7.3. AVRRD-03
13.7.4. JR-162
13.7.5. MOSS-GAA
13.7.6. OXY-2810
13.7.7. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Lysosomal Alpha Glucosidase Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Lysosomal Alpha Glucosidase Market: Market Share Analysis
14.2. Lysosomal Alpha Glucosidase Distributors and Customers
14.3. Lysosomal Alpha Glucosidase Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amicus Therapeutics Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Audentes Therapeutics Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Etubics Corp
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Genzyme Corp
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. greenovation Biotech GmbH
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Huons Co Ltd
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. JCR Pharmaceuticals Co Ltd
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Oxyrane Belgium NV
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Pharming Group NV
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Sarepta Therapeutics Inc
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
